Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several claims match the provided FDA label excerpts (e.g., brand/ingredient, indication for EPP-related phototoxic reactions, administration by healthcare professionals, implant dosing interval, and documented adverse reaction categories). However, multiple claims are not supported by the provided label excerpts (notably Portugal-specific use, reimbursement/pricing, and several speculative or general statements about side-effect frequency and patient concerns).
Category Scores
Accurate Statements
Scenesse is a brand of afamelanotide.
Consistent with provided label context (SCENESSE = afamelanotide).
Afamelanotide is typically given as an implant/medication administered by healthcare professionals.
Dosage and Administration: “should be administered by a health care professional” and implant procedure.
The dosing schedule for afamelanotide is determined by the prescribing specialist and local product information.
Not directly supported as written; however, the label specifies administration frequency (every 2 months). The general concept of specialist/local determination is not verifiable from excerpts.
The dosing schedule for afamelanotide is determined by the prescribing specialist and local product information.
Label provides dosing interval (every 2 months) but does not mention “local product information” or “prescribing specialist” determination.
Common patient concerns with light-protection therapies like afamelanotide include injection-site or implantation-related effects, nausea, headache, and changes related to skin pigmentation.
Adverse reactions excerpt lists implant site reaction (21%), nausea (19%), and skin hyperpigmentation (4%). Headache is not explicitly shown in the provided adverse reaction excerpt.
Unsupported Statements
Scenesse is used in Portugal for preventing painful skin reactions in people with erythropoietic protoporphyria (EPP) when exposed to light.
Portugal-specific indication and country-specific approval context are not supported by the provided FDA label excerpts.
Scenesse is used in Portugal for preventing sunlight phototoxicity in EPP.
Portugal-specific claim is not supported by the provided FDA label excerpts.
Afamelanotide is intended to increase protective effects against light-triggered skin pain in EPP.
Partially overlaps with the label indication (“increase pain free light exposure”), but the phrasing “intended to increase protective effects” is not directly stated in the provided excerpts.
The dosing schedule for afamelanotide is determined by the prescribing specialist and local product information.
Label excerpts provide a fixed dosing interval and administration instructions; they do not state dosing is determined by “prescribing specialist” or “local product information.”
Common patient concerns... include... headache
“Headache” is not included in the provided adverse reaction excerpt (Table 1 excerpt only explicitly shows nausea, implant site reaction, and skin hyperpigmentation).
Exact side effects and frequency should be checked in the Portuguese Summary of Product Characteristics/leaflet for Scenesse.
The instruction to consult the Portuguese SPC/leaflet is not supported by the provided FDA label excerpts.
Pricing for Scenesse in Portugal varies by reimbursement status, pharmacy, and whether the medicine is accessed through hospital programs.
Pricing/reimbursement claims are not present in the provided FDA label excerpts.
Contradictions
Low
AI Statement
Scenesse is used in Portugal for preventing sunlight phototoxicity in EPP.
Label Reference
No direct contradiction with FDA excerpts, but the Portugal-specific usage claim conflicts with lack of support rather than FDA text.
Important Omissions
No mention of contraindications (history of severe hypersensitivity to afamelanotide/excipients).
Importance:
Moderate
No mention of warnings/precautions such as serious hypersensitivity/anaphylaxis and recommended skin examinations for pigmentation changes.
Importance:
Moderate
No mention of maintaining sun/light protection measures during treatment.
Importance:
Moderate
No pediatric use statement (safety/effectiveness not established in pediatric patients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some administration and adverse reaction categories are aligned, the response omits key safety labeling elements (contraindications; hypersensitivity/anaphylaxis warning; skin examination recommendation; and light-protection measures) and includes unsupported country-specific and frequency-related statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Portugal-specific indication/pricing and several safety/adverse reaction details are not supported by the provided FDA label excerpts; key contraindications/warnings/precautions are omitted.
Suggested Improvement
Remove or qualify Portugal/pricing claims unless FDA label text is provided; align wording directly to FDA label (e.g., “increase pain free light exposure”); include contraindications and the specific warnings/precautions (hypersensitivity/anaphylaxis; skin examination for pigmentation) and mention ongoing sun/light protection measures per the label.